{
    "clinical_study": {
        "@rank": "164836", 
        "arm_group": {
            "arm_group_label": "Treatment (docetaxel, hyperfractionated IMRT)", 
            "arm_group_type": "Experimental", 
            "description": "Patients receive docetaxel IV over 1 hour on days 1 and 8 and undergo hyperfractionated IMRT BID on days 1-5 and 8-12 (20 fractions)."
        }, 
        "brief_summary": {
            "textblock": "This phase II trial studies how well radiation therapy and docetaxel work in treating\n      patients with human papillomavirus (HPV)-related oropharyngeal cancer. Radiation therapy\n      uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as docetaxel,\n      work in different ways to stop the growth of tumor cells, either by killing the cells or by\n      stopping them from dividing. Giving radiation therapy with docetaxel my kill more tumor\n      cells."
        }, 
        "brief_title": "Radiation Therapy and Docetaxel in Treating Patients With HPV-Related Oropharyngeal Cancer", 
        "condition": [
            "Human Papilloma Virus Infection", 
            "Stage I Squamous Cell Carcinoma of the Oropharynx", 
            "Stage II Squamous Cell Carcinoma of the Oropharynx", 
            "Stage III Squamous Cell Carcinoma of the Oropharynx", 
            "Stage IVA Squamous Cell Carcinoma of the Oropharynx", 
            "Stage IVB Squamous Cell Carcinoma of the Oropharynx", 
            "Tongue Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Squamous Cell", 
                "Papilloma", 
                "Virus Diseases", 
                "Tongue Neoplasms", 
                "Oropharyngeal Neoplasms", 
                "Warts", 
                "Papillomavirus Infections"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. To assess the cumulative incidence of local/regional failure at 2 years after study\n      registration.\n\n      SECONDARY OBJECTIVES:\n\n      I. To characterize the rate of acute grade 3 or higher functional mucosal adverse events (up\n      to 1 month post-radiation therapy [XRT]) associated with adjuvant docetaxel +\n      hyperfractionated radiotherapy (key secondary endpoint).\n\n      II. To assess changes in overall survival, disease-free survival, distant failure rates, and\n      quality of life (QOL) associated with adjuvant docetaxel and hyperfractionated radiation.\n\n      III. To characterize other acute adverse events (up to 1 month post-XRT) and late grade 3 or\n      higher non-hematologic adverse events (up to 2 years post-XRT) associated with adjuvant\n      docetaxel + hyperfractionated radiotherapy.\n\n      OUTLINE:\n\n      Patients receive docetaxel intravenously (IV) over 1 hour on days 1 and 8 and undergo\n      hyperfractionated intensity-modulated radiation therapy (IMRT) twice daily (BID) on days 1-5\n      and 8-12 (20 fractions).\n\n      After completion of study treatment, patients are followed up at 14 days, 1 month, every 3\n      months for 2 years, every 6 months for 1 year and then annually for 2 years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histological confirmation of HPV+ squamous cell carcinoma of the oropharynx; HPV\n             positivity will be defined as positive staining for p16 on immunohistochemistry (IHC)\n\n          -  Gross total surgical resection with curative intent of the primary tumor and at least\n             unilateral neck dissection within 7 weeks of registration\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1\n\n          -  Smoking history < 10 pack years or equivalent 10 year history of tobacco product use\n\n          -  Absence of distant metastases on standard diagnostic work-up =< 8 weeks prior to\n             registration; (chest computed tomography [CT], chest x-ray [CXR], positron emission\n             tomography [PET]/CT, etc.)\n\n          -  Must have one of the following risk factors:\n\n               -  Lymph node > 3 cm\n\n               -  2 or more positive lymph nodes\n\n               -  Perineural invasion\n\n               -  Lymphovascular space invasion\n\n               -  T3 or microscopic T4a primary disease\n\n               -  Lymph node extracapsular extension\n\n          -  Absolute neutrophil count (ANC) >= 1500/mm^3\n\n          -  Platelet count >= 100,000/mm^3\n\n          -  Hemoglobin >= 9.0 g/dL\n\n          -  Direct bilirubin within upper limit of normal (ULN)\n\n          -  Creatinine =< ULN x 1.5\n\n          -  Negative pregnancy test done =< 7 days prior to registration, for women of\n             childbearing potential only\n\n          -  Ability to complete questionnaire(s) by themselves or with assistance\n\n          -  Provide informed written consent\n\n          -  Willingness to return to enrolling institution for follow-up (during the active\n             monitoring phase of the study)\n\n        Exclusion Criteria:\n\n          -  Any significant tobacco history within the past five years\n\n          -  Any of the following:\n\n               -  Pregnant women\n\n               -  Nursing women\n\n               -  Men or women of childbearing potential who are unwilling to employ adequate\n                  contraception\n\n          -  Co-morbid systemic illnesses or other severe concurrent disease which, in the\n             judgment of the investigator, would make the patient inappropriate for entry into\n             this study or interfere significantly with the proper assessment of safety and\n             toxicity of the prescribed regimens\n\n          -  Immunocompromised patients and patients known to be human immunodeficiency virus\n             (HIV) positive\n\n          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active\n             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac\n             arrhythmia, or psychiatric illness/social situations that would limit compliance with\n             study requirements\n\n          -  Receiving any other investigational agent which would be considered as a treatment\n             for the primary neoplasm\n\n          -  Other active malignancy =< 5 years prior to registration; EXCEPTIONS: non-melanotic\n             skin cancer or carcinoma-in-situ of the cervix; NOTE: if there is a history or prior\n             malignancy, they must not be receiving other specific treatment for their cancer\n\n          -  History of myocardial infarction =< 180 days prior to registration, or congestive\n             heart failure requiring use of ongoing maintenance therapy for life-threatening\n             ventricular arrhythmias\n\n          -  Prior history of radiation therapy to the affected site\n\n          -  History of connective tissue disorders such as rheumatoid arthritis, lupus, or\n             Sjogren's disease\n\n          -  Presence of any of the following risk factors after surgery:\n\n               -  Any positive surgical margin\n\n               -  Adenopathy below the clavicles\n\n          -  Prior systemic chemotherapy for the study cancer; NOTE: prior chemotherapy for a\n             different cancer is allowable\n\n          -  History of allergic reaction to docetaxel\n\n          -  Receiving any medications or substances that are strong or moderate inhibitors of\n             cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4)\n\n               -  Use of strong or moderate inhibitors is prohibited =< 7 days prior to\n                  registration\n\n          -  Receiving any medications or substances that are inducers of CYP3A4\n\n               -  Use of inducers is prohibited =< 12 days prior to registration"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 27, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01932697", 
            "org_study_id": "MC1273", 
            "secondary_id": [
                "NCI-2013-01652", 
                "12-005272", 
                "MC1273", 
                "P30CA015083"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment (docetaxel, hyperfractionated IMRT)", 
                "description": "Given IV", 
                "intervention_name": "docetaxel", 
                "intervention_type": "Drug", 
                "other_name": [
                    "RP 56976", 
                    "Taxotere", 
                    "TXT"
                ]
            }, 
            {
                "arm_group_label": "Treatment (docetaxel, hyperfractionated IMRT)", 
                "description": "Undergo hyperfractionated IMRT", 
                "intervention_name": "intensity-modulated radiation therapy", 
                "intervention_type": "Radiation", 
                "other_name": "IMRT"
            }, 
            {
                "arm_group_label": "Treatment (docetaxel, hyperfractionated IMRT)", 
                "description": "Undergo hyperfractionated IMRT", 
                "intervention_name": "hyperfractionated radiation therapy", 
                "intervention_type": "Radiation"
            }, 
            {
                "arm_group_label": "Treatment (docetaxel, hyperfractionated IMRT)", 
                "description": "Ancillary studies", 
                "intervention_name": "quality-of-life assessment", 
                "intervention_type": "Procedure", 
                "other_name": "quality of life assessment"
            }, 
            {
                "arm_group_label": "Treatment (docetaxel, hyperfractionated IMRT)", 
                "description": "Correlative studies", 
                "intervention_name": "laboratory biomarker analysis", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Docetaxel"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 28, 2014", 
        "location": {
            "contact": {
                "email": "ma.daniel@mayo.edu", 
                "last_name": "Daniel J. Ma", 
                "phone": "507-284-2511"
            }, 
            "facility": {
                "address": {
                    "city": "Rochester", 
                    "country": "United States", 
                    "state": "Minnesota", 
                    "zip": "55905"
                }, 
                "name": "Mayo Clinic"
            }, 
            "investigator": {
                "last_name": "Daniel J. Ma", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase II Evaluation of Adjuvant Hyperfractionated Radiation and Docetaxel for HPV Associated Oropharynx Cancer", 
        "other_outcome": [
            {
                "description": "These markers will be correlated with clinical endpoints like acute adverse events, cumulative incidence rates of local/regional failure, overall survival, and disease-free survival.", 
                "measure": "E6/E7 messenger ribonucleic acid (mRNA) of HPV16, assessed on a chromogenic RNA in situ hybridization (ISH) assay called RNAscope", 
                "safety_issue": "No", 
                "time_frame": "Baseline"
            }, 
            {
                "description": "These markers will be correlated with clinical endpoints like acute adverse events, cumulative incidence rates of local/regional failure, overall survival, and disease-free survival.", 
                "measure": "Changes in transforming growth factor (TGF)-beta1 levels", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 1 week post-radiation"
            }
        ], 
        "overall_official": {
            "affiliation": "Mayo Clinic", 
            "last_name": "Daniel Ma", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The 2-year cumulative incidence of local/regional failure will be estimated by the competing risk method, where the competing risks are distant failures and deaths from other causes (i.e. deaths from distant failure or non-oropharynx cancer).", 
            "measure": "Cumulative incidence of local/regional failure", 
            "safety_issue": "No", 
            "time_frame": "Up to 2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01932697"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Incidence of acute grade 3 or higher functional mucosal adverse events graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 1 month post-hyperfractionated radiation therapy"
            }, 
            {
                "description": "The distribution of OS will be estimated using the method of Kaplan-Meier.", 
                "measure": "Overall survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "From registration to death due to any cause, assessed up to 5 years"
            }, 
            {
                "description": "The distribution of DFS will be estimated using the method of Kaplan-Meier.", 
                "measure": "Disease-free survival (DFS)", 
                "safety_issue": "No", 
                "time_frame": "From registration to the first of either disease recurrence or death, assessed up to 5 years"
            }, 
            {
                "description": "The 2-year cumulative incidence of distant failure will be estimated by the competing risk method, where the competing risks are local/regional failures and deaths from other causes (i.e. deaths from local/regional failure or non-oropharynx cancer).", 
                "measure": "Distant failure rates", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 years"
            }, 
            {
                "description": "QOL scores will be explored descriptively. In addition, differences between post-baseline and baseline QOL scores will be analyzed using a paired-sample t-test or the nonparametric equivalent to see if the QOL tends to improve over time with treatment.", 
                "measure": "Change in QOL measured using the Xerostomia- Related Quality of Life Scale (XeQOLS) form, European Quality of Life (EuroQol) 5D (Eq-5D), Functional Assessment of Cancer Therapy Head and Neck (FACT H& N) (version 4), and Dermatology Life Quality Index", 
                "safety_issue": "No", 
                "time_frame": "Baseline to up to 24 months post-treatment"
            }, 
            {
                "description": "Swallowing will be scored (yes, no) for aspiration, penetration, velopharyngeal incompetence, epiglottic inversion, tongue base retraction, and pharyngeal swallow response using the metric outlined by Eisbruch et al. The swallowing questions will be explored descriptively to detect patterns and substantial changes over time. In addition, McNemar's test for paired samples will be used to see if the swallowing questions significantly change over time for each post-baseline time point.", 
                "measure": "Change in swallowing studies", 
                "safety_issue": "No", 
                "time_frame": "Baseline to up to 12 months post-treatment"
            }, 
            {
                "description": "The maximum grade for each type of acute adverse event will be recorded for each patient, and frequency tables will be reviewed to determine patterns, especially focusing on grade 3+ adverse events, regardless of attribution to the study treatment.", 
                "measure": "Incidence of acute adverse events graded according to NCI CTCAE version 4.0", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 1 month post-XRT"
            }, 
            {
                "description": "The maximum grade for each type of adverse event will be recorded for each patient for up to 2 years post-treatment, and frequency tables will be reviewed to determine patterns, especially focusing on grade 3+ non-hematologic adverse events, regardless of attribution to the study treatment.", 
                "measure": "Incidence of late adverse events graded according to NCI CTCAE version 4.0", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 2 years post-treatment"
            }
        ], 
        "source": "Mayo Clinic", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Mayo Clinic", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}